MY ACCOUNT | NEWSLETTER |

Minnesota zoo sees birth of rare cubs


Tiger specialists, the Minnesota Zoo, has welcomed rare Amur Tiger cubs in early May. Four were born to longtime zoo resident, Sundari, though three have survived to this time. Litters of four or more often have fatalities, according to the zoo.

The trio and their mom, Sundari, have been cared for by the team at the zoo, which has participated in the Association of Zoos and Aquariums Amur tiger Species Survival Plan (SSP).

“These cubs represent a major, positive step forward in our efforts to support the global population of Amur tigers," said John Frawley, director of the Minnesota Zoo. “Having three thriving cubs, and a mother who is successfully raising them, is a true testament to the care and dedication provided by our incredible team of zookeepers and veterinary staff.”

The initial months of the cubs’ lives are essential for healthy development, and the zoo is hopeful the remaining cubs will survive. Only 500 Amur Tigers are left in the world at this point, so the project is hoped to help the species survive through conservation and breeding. 

The cubs will be cared for by staff along with their mother in a space not visible to visitors. “Dari has proven to be an incredible mother to these cubs,” said Dr. Taylor Yaw, chief animal care, health, and conservation officer at Minnesota Zoo. “She has been attentive, nursing around the clock, and keeping the cubs groomed and by her side. The deep bond and trust that our keepers have formed with Dari over the years has allowed us to monitor the cubs and safely separate her from the cubs in order to perform routine health checks.”


Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Comparison of two host cell range variants of feline immunodeficiency virus

Like0
Dislike0

Canine babesiosis: a perspective on clinical complications, biomarkers, and treatment

Like0
Dislike0

The use of growth promoters in swine nutrition: Problems and perspectives concerning public health and swine production

Like0
Dislike0

Penn Vet Announces Interim Leadership for the Department of Clinical Sciences and Advanced Medicine, and Ryan Hospital

Like0
Dislike0

Parnell Launches nixiFLOR® - First FDA-Approved Generic Florfenicol + Flunixin Combination for BRD

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top